Immunocore Holdings plc (IMCR)

Immunocore Holdings Income Statement

Financials in millions GBP. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	249.43	174.36	36.48	37.64	32.09
Revenue Growth (YoY)	43.05%	377.91%	-3.08%	17.32%	8.52%
Cost of Revenue	1.04	1.09	0	0	0
Gross Profit	248.39	173.27	36.48	37.64	32.09
Selling, General & Admin	144.5	123.06	110.82	57.18	55.23
Research & Development	163.55	101.92	100.25	93.51	124.99
Other Operating Expenses	0	0	0	-5.3	-0.23
Operating Expenses	308.04	224.98	211.07	145.38	179.99
Operating Income	-59.65	-51.71	-174.59	-107.74	-147.9
Interest Expense / Income	5.15	5.41	5.57	4.22	11.72
Other Expense / Income	-3.91	-16.23	-0.28	-2.76	-1.89
Pretax Income	-60.89	-40.88	-179.88	-109.2	-157.74
Income Tax	-5.6	11.66	0.15	-16.58	-27.82
Net Income	-55.29	-52.54	-180.03	-92.62	-129.91
Shares Outstanding (Basic)	49	46	42	41	41
Shares Outstanding (Diluted)	49	46	42	-	-
Shares Change	6.94%	7.59%	4.29%	-	-
EPS (Basic)	-1.13	-1.15	-4.24	-3.49	-5.83
EPS (Diluted)	-1.13	-1.15	-4.24	-3.49	-5.83
Free Cash Flow	-2.49	-51.41	-144.39	-129.94	-150.47
Free Cash Flow Per Share	-0.05	-1.12	-3.40	-3.19	-3.69
Gross Margin	99.58%	99.38%	100.00%	100.00%	100.00%
Operating Margin	-23.91%	-29.66%	-478.53%	-286.22%	-460.95%
Profit Margin	-22.17%	-30.13%	-493.45%	-246.04%	-404.89%
Free Cash Flow Margin	-1.00%	-29.48%	-395.75%	-345.18%	-468.97%
EBITDA	-50	-28.06	-164.64	-93.76	-134.5
EBITDA Margin	-20.05%	-16.09%	-451.26%	-249.08%	-419.17%
Depreciation & Amortization	5.74	7.41	9.67	11.22	11.52
EBIT	-55.74	-35.47	-174.31	-104.98	-146.01
EBIT Margin	-22.35%	-20.35%	-477.76%	-278.89%	-455.06%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).